Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow.
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2013
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms MRD-1
- Sponsors Novartis
- 29 Dec 2009 Trial acronym MRD-1 identified as reported by ClinicalTrials.gov.
- 29 Dec 2009 Actual patient number (96) added as reported by ClinicalTrials.gov.
- 29 Dec 2009 Planned end date (Nov 2008) added as reported by ClinicalTrials.gov.